Bonviva® 150 mg film-coated tablets
Bonviva® is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
A reduction in the risk of vertebral fractures has been demonstrated; efficacy in femoral neck fractures has not been established.
Access technical file Bonviva® 150 mg film-coated tablets
Bonviva® 150 mg film-coated tablets
Ownership: Atnahs Pharma Netherlands B.V.
Comercialized by: Marketed and distributed in Spain by Laboratorios Rubió as a local representative.
Last update: July 2024
The information contained in this area is directed exclusively to healthcare professionals with the capacity to prescribe or dispense medications.